Precision medicine strategy in pancreatic ductal adenocarcinoma
To conclude, molecular profiling identified actionable alterations in 20% of PDAC patients. MMT was associated with a significant survival benefit, supporting molecular profiling into routine management, especially with the perspective of KRAS inhibitors.
Authors
- Etienne Rouleau (ORCID: https://orcid.org/0000-0002-6316-5668)
- Mohamed Amine Bani (ORCID: https://orcid.org/0000-0003-4834-4905)
- Rémy Barbe (ORCID: https://orcid.org/0000-0002-1851-1787)
- C. Smolenschi
- Maximiliano Gelli (ORCID: https://orcid.org/0000-0001-9807-4021)
- Marine Valéry (ORCID: https://orcid.org/0000-0002-7787-6911)
- Alina Fuerea (ORCID: https://orcid.org/0009-0002-7074-0189)
- L Swales
- T. Pudlarz (ORCID: https://orcid.org/0009-0006-6591-2213)
- Alice Boilève (ORCID: https://orcid.org/0000-0003-3708-4909)
- Michel Ducreux (ORCID: https://orcid.org/0000-0001-8649-7449)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- Anthony Tarabay
- V. Boige
- Elie Akoury
Institutions
- Inserm (FR)
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105899
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05